Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Post by stockfyon Jan 20, 2021 5:32pm
251 Views
Post# 32340413

Q3: Employees bought at C$1.27 and CPH repurchased at C$1.14

Q3: Employees bought at C$1.27 and CPH repurchased at C$1.14Some emotional short-sighted investors sold dirt-cheap CPH at C$0.85 two days ago while ignoring the company's strong fundamentals and super low key metrics.  

In the meantime, CPH bought back 30,000 shares at C$1.14 in Q3, read its quarterly report: 

"During the period ended September 30, 2020, the Company purchased for cancellation 30,000 common shares at an average price of CDN1.14 per common share."


Additionally, CPH issued 13,000 shares for its employees at C$1.27, facts below:
 
"Share purchase plan: The Company's ESPP allows employees and directors to share in the growth of the Company through share ownership. Through the ESPP, employees and directors may contribute amounts to purchase shares of the Company at a 15% discount from the prevailing trading price. Plan members must hold their shares for a period of at least six months before they can be sold. During the three months ended September 30, 2020, 13,077 shares were issued under the ESPP at weighted average trading price of CDN$1.27 per common share. "
 



<< Previous
Bullboard Posts
Next >>